LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Public ClinicalTrials.gov record NCT00525148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST criteria in patients with advanced NSCLC Stage IIIB or IV whose tumors harbor activating mutations within exon 18 to exon 21 of the EGFR receptor. Patients progressing or relapsing after one prior cytotoxic chemotherapy regimen as well as chemotherapy naïve patients (only in stage 2) will be allowed to enter into the trial.
Study identification
- NCT ID
- NCT00525148
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Type not available)
- Primary completion
- Feb 2010 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Sep 16, 2016
2007 – 2015
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.22.28 Boehringer Ingelheim Investigational Site | Bakersfield | California | — | — |
| 1200.22.32 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1200.22.4 Boehringer Ingelheim Investigational Site | Mission Hills | California | — | — |
| 1200.22.16 Boehringer Ingelheim Investigational Site | Orange | California | — | — |
| 1200.22.19 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1200.22.29 Boehringer Ingelheim Investigational Site | North Miami Beach | Florida | — | — |
| 1200.22.10 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1200.22.18 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1200.22.3 Boehringer Ingelheim Investigational Site | Bethesda | Maryland | — | — |
| 1200.22.14 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1200.22.24 Boehringer Ingelheim Investigational Site | Flint | Michigan | — | — |
| 1200.22.5 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1200.22.15 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1200.22.26 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1200.22.1 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1200.22.27 Boehringer Ingelheim Investigational Site | Syracuse | New York | — | — |
| 1200.22.25 Boehringer Ingelheim Investigational Site | Valhalla | New York | — | — |
| 1200.22.6 Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| 1200.22.7 Boehringer Ingelheim Investigational Site | Wynnewood | Pennsylvania | — | — |
| 1200.22.22 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 1200.22.31 Boehringer Ingelheim Investigational Site | Fairfax | Virginia | — | — |
| 1200.22.40 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 1200.22.33 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00525148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2016 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00525148 live on ClinicalTrials.gov.